… growth factor receptor (EGFR) tyrosine kinase inhibitors via hepatocyte growth factor (HGF) …
However, the experiment on mouse model of pancreatic cancer showed that desmoplastic …

… pancreatic cancer [75], while circulating exosomal macrophage migration inhibitory factor (…
the human epidermal growth factor receptor 2 (HER2), the epidermal growth factor receptor (…

… growth factor-beta (TGF-β) [31]. Blocking of this pleotropic immunosuppressive cytokine
by inhibitory drugs is pivotal for the suppression of cancer growth and progression [54, 55]. …

… Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide and …
growth factors and proinflammatory cytokines such as TGFβ, vascular endothelial growth factor (…

… In our previous clinical studies, we designed a CAR against epidermal growth factor receptor
(EGFR) and demonstrated the safety and efficacy of infusion of anti-EGFR CAR T (CAR T–…

… approaches and challenges to early detection of pancreatic cancer using molecular (DNA-based)
techniques. We discuss the patients at high risk of pancreatic cancer best targeted for …

… rate of pancreatic cancer was is only 7.2% and the incidence of pancreatic cancer is expected
to … One possible mechanism is the activation of the transforming growth factor-β1 (TGF-β1) …

… to tumor progression through multiple factors, for example collagen I, epidermal growth factor
(EGF), hepatocyte growth factor (… Another challenge is the design and analysis of cellular …

… , and metastasis, the hepatocyte growth factor (HGF) receptor – also called tyrosine kinase
MET – is a promising target in cancer therapy as its axis is involved in several different …

… We hypothesise that a CSC-supportive environment will enable a more faithful approximation
of the patients’ PDAC characteristics than directed differentiation via growth factors (as in …